MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery

John G. Gaudet, Gene T. Yocum, Susie So-Hyun Lee, Anna Granat, Maya Mikami, E. Sander Connolly, Eric J. Heyer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Approximately 25% of elderly patients scheduled for carotid endarterectomy (CEA) develop post-operative cognitive dysfunction (CD). We tested the hypothesis that the plasma levels of matrix metalloproteinase 9 (MMP-9) are predictive of moderate to severe CD after CEA. A total of 73 patients were prospectively enrolled in this Institutional Review Board-approved study. Plasma samples were obtained at baseline and day 1 post-surgery. We measured the plasma concentrations of both MMP-9 and its inhibitor, tissue inhibitor of metalloproteinases 1 (TIMP-1). We estimated the MMP-9 activity by calculating the MMP-9:TIMP-1 ratio. The cognitive performance day 1 post-surgery was quantified with z-scores, using a control group who were undergoing spinal surgery. The criteria used to define CD was performance of ≥1.5 standard deviations worse than the control group; approximately 19% of eligible patients developed CD. Compared to patients without CD, this group had both higher total (81.66 ± 12.25 ng/mL versus [vs.] 43.18 ± 4.44 ng/mL, p = 0.005) and activity (0.88 ± 0.24 ng/mL vs. 0.54 ± 0.06 ng/mL, p = 0.003) MMP-9 levels at baseline. All of the results were adjusted for age, diabetes and neurovascular symptoms.

Original languageEnglish (US)
Pages (from-to)436-440
Number of pages5
JournalJournal of Clinical Neuroscience
Volume17
Issue number4
DOIs
StatePublished - Apr 2010
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 9
Tissue Inhibitor of Metalloproteinase-1
Carotid Endarterectomy
Control Groups
Research Ethics Committees
Cognitive Dysfunction

Keywords

  • Aged 60 and over
  • Carotid
  • Cognition disorders
  • Endarterectomy
  • Matrix metalloproteinase 9
  • Post-operative complications

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

Cite this

Gaudet, J. G., Yocum, G. T., Lee, S. S-H., Granat, A., Mikami, M., Sander Connolly, E., & Heyer, E. J. (2010). MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery. Journal of Clinical Neuroscience, 17(4), 436-440. https://doi.org/10.1016/j.jocn.2009.07.103

MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery. / Gaudet, John G.; Yocum, Gene T.; Lee, Susie So-Hyun; Granat, Anna; Mikami, Maya; Sander Connolly, E.; Heyer, Eric J.

In: Journal of Clinical Neuroscience, Vol. 17, No. 4, 04.2010, p. 436-440.

Research output: Contribution to journalArticle

Gaudet, JG, Yocum, GT, Lee, SS-H, Granat, A, Mikami, M, Sander Connolly, E & Heyer, EJ 2010, 'MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery', Journal of Clinical Neuroscience, vol. 17, no. 4, pp. 436-440. https://doi.org/10.1016/j.jocn.2009.07.103
Gaudet, John G. ; Yocum, Gene T. ; Lee, Susie So-Hyun ; Granat, Anna ; Mikami, Maya ; Sander Connolly, E. ; Heyer, Eric J. / MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery. In: Journal of Clinical Neuroscience. 2010 ; Vol. 17, No. 4. pp. 436-440.
@article{1beed0bc63c74c70878607b274c37bb4,
title = "MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery",
abstract = "Approximately 25{\%} of elderly patients scheduled for carotid endarterectomy (CEA) develop post-operative cognitive dysfunction (CD). We tested the hypothesis that the plasma levels of matrix metalloproteinase 9 (MMP-9) are predictive of moderate to severe CD after CEA. A total of 73 patients were prospectively enrolled in this Institutional Review Board-approved study. Plasma samples were obtained at baseline and day 1 post-surgery. We measured the plasma concentrations of both MMP-9 and its inhibitor, tissue inhibitor of metalloproteinases 1 (TIMP-1). We estimated the MMP-9 activity by calculating the MMP-9:TIMP-1 ratio. The cognitive performance day 1 post-surgery was quantified with z-scores, using a control group who were undergoing spinal surgery. The criteria used to define CD was performance of ≥1.5 standard deviations worse than the control group; approximately 19{\%} of eligible patients developed CD. Compared to patients without CD, this group had both higher total (81.66 ± 12.25 ng/mL versus [vs.] 43.18 ± 4.44 ng/mL, p = 0.005) and activity (0.88 ± 0.24 ng/mL vs. 0.54 ± 0.06 ng/mL, p = 0.003) MMP-9 levels at baseline. All of the results were adjusted for age, diabetes and neurovascular symptoms.",
keywords = "Aged 60 and over, Carotid, Cognition disorders, Endarterectomy, Matrix metalloproteinase 9, Post-operative complications",
author = "Gaudet, {John G.} and Yocum, {Gene T.} and Lee, {Susie So-Hyun} and Anna Granat and Maya Mikami and {Sander Connolly}, E. and Heyer, {Eric J.}",
year = "2010",
month = "4",
doi = "10.1016/j.jocn.2009.07.103",
language = "English (US)",
volume = "17",
pages = "436--440",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "4",

}

TY - JOUR

T1 - MMP-9 levels in elderly patients with cognitive dysfunction after carotid surgery

AU - Gaudet, John G.

AU - Yocum, Gene T.

AU - Lee, Susie So-Hyun

AU - Granat, Anna

AU - Mikami, Maya

AU - Sander Connolly, E.

AU - Heyer, Eric J.

PY - 2010/4

Y1 - 2010/4

N2 - Approximately 25% of elderly patients scheduled for carotid endarterectomy (CEA) develop post-operative cognitive dysfunction (CD). We tested the hypothesis that the plasma levels of matrix metalloproteinase 9 (MMP-9) are predictive of moderate to severe CD after CEA. A total of 73 patients were prospectively enrolled in this Institutional Review Board-approved study. Plasma samples were obtained at baseline and day 1 post-surgery. We measured the plasma concentrations of both MMP-9 and its inhibitor, tissue inhibitor of metalloproteinases 1 (TIMP-1). We estimated the MMP-9 activity by calculating the MMP-9:TIMP-1 ratio. The cognitive performance day 1 post-surgery was quantified with z-scores, using a control group who were undergoing spinal surgery. The criteria used to define CD was performance of ≥1.5 standard deviations worse than the control group; approximately 19% of eligible patients developed CD. Compared to patients without CD, this group had both higher total (81.66 ± 12.25 ng/mL versus [vs.] 43.18 ± 4.44 ng/mL, p = 0.005) and activity (0.88 ± 0.24 ng/mL vs. 0.54 ± 0.06 ng/mL, p = 0.003) MMP-9 levels at baseline. All of the results were adjusted for age, diabetes and neurovascular symptoms.

AB - Approximately 25% of elderly patients scheduled for carotid endarterectomy (CEA) develop post-operative cognitive dysfunction (CD). We tested the hypothesis that the plasma levels of matrix metalloproteinase 9 (MMP-9) are predictive of moderate to severe CD after CEA. A total of 73 patients were prospectively enrolled in this Institutional Review Board-approved study. Plasma samples were obtained at baseline and day 1 post-surgery. We measured the plasma concentrations of both MMP-9 and its inhibitor, tissue inhibitor of metalloproteinases 1 (TIMP-1). We estimated the MMP-9 activity by calculating the MMP-9:TIMP-1 ratio. The cognitive performance day 1 post-surgery was quantified with z-scores, using a control group who were undergoing spinal surgery. The criteria used to define CD was performance of ≥1.5 standard deviations worse than the control group; approximately 19% of eligible patients developed CD. Compared to patients without CD, this group had both higher total (81.66 ± 12.25 ng/mL versus [vs.] 43.18 ± 4.44 ng/mL, p = 0.005) and activity (0.88 ± 0.24 ng/mL vs. 0.54 ± 0.06 ng/mL, p = 0.003) MMP-9 levels at baseline. All of the results were adjusted for age, diabetes and neurovascular symptoms.

KW - Aged 60 and over

KW - Carotid

KW - Cognition disorders

KW - Endarterectomy

KW - Matrix metalloproteinase 9

KW - Post-operative complications

UR - http://www.scopus.com/inward/record.url?scp=77349100804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77349100804&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2009.07.103

DO - 10.1016/j.jocn.2009.07.103

M3 - Article

VL - 17

SP - 436

EP - 440

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 4

ER -